MARKET

SRNE

SRNE

Sorrento Thera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.06
+0.31
+4.00%
After Hours: 8.11 +0.05 +0.62% 19:59 07/10 EDT
OPEN
7.89
PREV CLOSE
7.75
HIGH
8.51
LOW
7.83
VOLUME
30.68M
TURNOVER
--
52 WEEK HIGH
10.00
52 WEEK LOW
1.390
MARKET CAP
1.69B
P/E (TTM)
-4.6931
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SRNE stock price target is 23.00 with a high estimate of 24.00 and a low estimate of 21.00.

EPS

SRNE News

More
Sorrento Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Sorrento Therapeutics, Inc. To Contact The Firm
Newsfile · 18h ago
SORRENTO THERAPEUTICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a  securities  class  action  lawsuit  has  been  filed  in  the  United States District Court for the Southern District of California against Sorrento Therapeutics, Inc.
GlobeNewswire · 2d ago
Sorrento Therapeutics Option Alert: Jan 15 $2.5 Calls Sweep (2) near the Ask: 700 @ $5.27 vs 8840 OI; Earnings 8/7 Before Open [est] Ref=$7.5999
Benzinga · 2d ago
Can This Coronavirus Stock Soar 230%? 5-Star Analyst Thinks So
TipRanks · 2d ago
Sorrento Therapeutics (SRNE) Stock Sinks As Market Gains: What You Should Know
Zacks · 3d ago
Has Sorrento Therapeutics (SRNE) Outpaced Other Medical Stocks This Year?
Zacks · 3d ago
Will Sorrento Therapeutics' Shares March Higher, Can It Continue?
Zacks · 3d ago
Sorrento Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Sorrento Therapeutics, Inc. To Contact The Firm
Newsfile · 3d ago

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About SRNE

Sorrento Therapeutics, Inc. is a clinical-stage and commercial biopharma company. The Company operates through two segments: Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T), antibody-drug conjugates (ADC), as well as bispecific antibody approaches. Additionally, Sorrento Therapeutics segment also includes Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system to potentially achieve improved efficacy and fewer adverse effects than standard parenteral immunotherapy. The Scilex segment is organized around its non-opioid pain management operations.
More

Webull offers kinds of Sorrento Therapeutics Inc stock information, including NASDAQ:SRNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRNE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SRNE stock methods without spending real money on the virtual paper trading platform.